This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davis, D. W. Articles by McConkey, D. J. Search for Related Content PubMed PubMed Citation Articles by Davis, D. W. Articles by McConkey, D. J.

Automated Quantification of Apoptosis after Neoadjuvant Chemotherapy for Breast Cancer

Early Assessment Predicts Clinical Response¹

Departments of Cancer Biology [D. W. D., D. J. M.], Radiation Oncology [T. A. B.], Biostatistics [K. R. H.], Pathology [A. A. S.], and Breast Medical Oncology [V. V.], The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030

Purpose: A large body of evidence implicates apoptosis in the effects of cancer chemotherapeutic agents on tumor cells in vitro and tumor xenografts in vivo, but the predictive value of apoptosis as an early marker for clinical response in cancer patients remains unclear.

Experimental Design: We developed an automated, laser scanning cytometer-based method to quantify the percentage of tumor cells containing DNA fragmentation characteristic of apoptosis in tumor sections. We measured levels of apoptosis in a panel of 15 matched, 18-gauge core breast cancer biopsies obtained before and 48 h after neoadjuvant therapy with docetaxel plus doxorubicin or paclitaxel as part of two prospective clinical trials.

Results: The results revealed a strongly significant (P = 0.0023) association between chemotherapy-induced apoptosis and pathological response.

Conclusions: If the results can be validated in a larger patient cohort, the method could be used to "tailor" therapy to optimize benefit in a patient-specific fashion.

This article has been cited by other articles:

				F. Al-Ejeh, J. M. Darby, K. Pensa, K. R. Diener, J. D. Hayball, and M. P. Brown In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen Clin. Cancer Res., September 15, 2007; 13(18): 5519s - 5527s. [Abstract] [Full Text] [PDF]

				S. E. Canfield, K. Zhu, S. A. Williams, and D. J. McConkey Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther., August 1, 2006; 5(8): 2043 - 2050. [Abstract] [Full Text] [PDF]

				T. A. Buchholz, A. K. Garg, N. Chakravarti, B. B. Aggarwal, F. J. Esteva, H. M. Kuerer, S. E. Singletary, G. N. Hortobagyi, L. Pusztai, M. Cristofanilli, et al. The Nuclear Transcription Factor {kappa}B/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer Clin. Cancer Res., December 1, 2005; 11(23): 8398 - 8402. [Abstract] [Full Text] [PDF]

				D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668 Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689. [Abstract] [Full Text] [PDF]

				D. W. Davis, K. Inoue, C. P. N. Dinney, D. J. Hicklin, J. L. Abbruzzese, and D. J. McConkey Regional Effects of an Antivascular Endothelial Growth Factor Receptor Monoclonal Antibody on Receptor Phosphorylation and Apoptosis in Human 253J B-V Bladder Cancer Xenografts Cancer Res., July 1, 2004; 64(13): 4601 - 4610. [Abstract] [Full Text] [PDF]

				A. M. Kamat, T. Karashima, D. W. Davis, L. Lashinger, M. Bar-Eli, R. Millikan, Y. Shen, C. P. N. Dinney, and D. J. McConkey The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo Mol. Cancer Ther., March 1, 2004; 3(3): 279 - 290. [Abstract] [Full Text]

				D. W. Davis, Y. Shen, N. A. Mullani, S. Wen, R. S. Herbst, M. O'Reilly, J. L. Abbruzzese, and D. J. McConkey Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors Clin. Cancer Res., January 1, 2004; 10(1): 33 - 42. [Abstract] [Full Text] [PDF]

				S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D. J. McConkey Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts Mol. Cancer Ther., September 1, 2003; 2(9): 835 - 843. [Abstract] [Full Text] [PDF]